GlassScriptPhysician profile
Siddharth Bhargava
NPI 1043849078
$3,654.09
in general payments reported to CMS, 2019-2025
10 companies · $592 in 2025
The $592 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $390 · 2023: $132 · 2024: $2,540 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,054 · Travel and Lodging: $1,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,053.95 |
| Travel and Lodging | $1,210.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,156.15 | 2022-2025 | Xen Glaucoma Treatment System |
| Sight Sciences, INC. | $740.09 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| New World Medical,INC. | $335.94 | 2024-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Biotissue Holdings INC. | $148.33 | 2024 | |
| Allergan, INC. | $99.99 | 2022 | |
| Alexion Pharmaceuticals, INC. | $69.45 | 2022 | |
| Harrow Eye, LLC | $35.99 | 2024 | Vevye |
| Thea Pharma INC. | $24.88 | 2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $23.55 | 2025 | Xdemvy |
| Alcon Vision LLC | $19.72 | 2024 | Hydrus Microstent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siddharth Bhargava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.